top of page
PRRT (1200 × 300 px).png

PRRT Resources


Watch "The Latest in PRRT" with Dr. Carina Mari Aparici. This presentation is part of the 2023 LACNETS Neuroendocrine Tumor Patient Education Conference held on June 17, 2023.

Nuclear Medicine Physician and Theranostics Director at Fred Hutchinson Cancer Center, Dr. Amir Iravani, shares the latest on Peptide Receptor Radionuclide Therapy (PRRT). Better understand the difference between beta and alpha PRRT, current trials and updates on PRRT for Lung NET, adolescents and dosimetry.

NET expert and radiologist Dr. Thomas Hope of UCSF addresses the latest in NET imaging and PRRT.

Nuclear Medicine Physician Dr. Erik Mittra provides an update on PRRT. Plus, hear from a NET patient who has received multiple rounds of PRRT treatments.

Nuclear medicine specialist Dr. Delpassand provides an update on the exciting advances in NET Management including Cu64 DOTATATE & Alpha PRRT.


PRRT Patient/Caregiver Stories

PRRT Patient/Caregiver Stories

Watch Now


Podcast 9 (Podcast) (1).png

Administrative Nurse Lindy Gardner of UCLA Health answers 10 common questions about the before, during and after of PRRT.

Podcast 9 (Podcast) (2).png

Nuclear Medicine Physician Dr. Martin Auerbach of UCLA Health answers 10 common questions about the decision-making process of PRRT.

Podcast 10 (Podcast) (1).png

Patient advocate Josh Mailman answers ten common questions about the past, present, and future of PRRT.



COMPOSE is an international phase III clinical study to evaluate the efficacy, safety and impact on quality of life of Targeted Radionuclide Therapy (PRRT) with no-carrier-added lutetium-177-edotreotide (n.c.a. 177Lu-edotreotide) compared to a standard therapy with either CAPTEM or everolimus or FOLFOX, in patients with well-differentiated advanced Grade 2 and Grade 3, somatostatin receptor-positive (SSTR+) neuroendocrine tumors of gastroenteric or pancreatic origin (G2 and G3 GEP-NETs).

The study is being conducted predominantly in Europe, North America, India and Australia, in approximately 10 countries and 40 sites. Learn more and join the study here.

RayzeBio is sponsoring the ACTION-1 study, a phase 1b/3 open-label study of 225Ac-DOTATATE (RYZ101) compared with standard of care therapy in patients with inoperable, advanced, SSTR+ well-differentiated GEP-NET that has progressed following treatment with 177Lu-DOTATATE/TOC. The phase 3 portion is currently enrolling. More information on this trial can be found here.


This is for informational use only. LACNETS is not endorsing or recommending any particular treatment or trials. LACNETS encourages you to discuss your individual needs and options with your medical team. For more information about available clinical trials, go to